Back to mobile site

JMP Securities Downgrades Ambrx Biopharma (AMAM) to Market Perform

January 10, 2024 4:14 AM EST Send to a Friend
JMP Securities analyst Reni Benjamin downgraded Ambrx Biopharma (NASDAQ: AMAM) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login